Featured Research

from universities, journals, and other organizations

Celecoxib (Celebrex) may be effective in preventing non-melanoma skin cancers

Date:
November 30, 2010
Source:
Journal of the National Cancer Institute
Summary:
Celecoxib (also known by its brand name Celebrex) may help prevent non-melanoma skin cancers in patients with extensive actinic keratosis, which is often a precursor to these cancers, according to a randomized clinical trial.

Celecoxib (also known by its brand name Celebrex) may help prevent nonmelanoma skin cancers in patients with extensive actinic keratosis, which is often a precursor to these cancers, according to a randomized clinical trial published online Nov. 29 in The Journal of the National Cancer Institute.

Nonmelanoma skin cancers -- including cutaneous squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs) -- are among the most common cancers in the United States. The incidence of these malignancies is rising and is beginning to occur more frequently in young adults. Exposure to UV radiation is believed to be one of the main causes. Existing methods of protecting against UV light, namely sunscreens, have only been modestly effective at reducing these cancers' incidence, so researchers have begun looking for other ways to prevent them. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits the enzyme cyclooxygenase 2, believed to be involved in the development of UV-induced nonmelanoma skin cancers.

To determine whether celecoxib reduces the incidence of new actinic keratosis, Craig A. Elmets, M.D., of the University of Alabama at Birmingham, and colleagues, conducted a double-blind, placebo-controlled randomized trial with 240 people with actinic keratoses, or precancerous skin lesions. They looked at the number of new lesions after 3, 6, and 9 months of therapy and at 2 months following the completion of therapy.

The researchers found that the number of new precancerous lesions in the group of people taking celecoxib and those taking the placebo was the same. However, by the end of the trial, those taking celecoxib had a statistically significant fewer number of nonmelanoma skin cancers compared with those in the placebo group.

The researchers write, "The findings of this study, which showed that the celecoxib-treated individuals developed fewer nonmelanoma skin cancers than placebo-treated individuals, suggest that cyclooxygenase inhibitors may provide an additional benefit to sunscreens in the prevention of nonmelanoma skin cancers."

The finding that celecoxib did not reduce the number of precancerous lesions was inconsistent with animal studies showing that celecoxib reduced both precancerous lesions and nonmelanoma skin cancers. However, the drug's efficacy against later stages of tumor development was consistent with findings of trials of celecoxib for colorectal adenoma.

The FDA terminated the study early, after preliminary findings from a concurrent trial of another cyclooxygenase 2 inhibitor showing an increased risk of cardiovascular adverse events. The fact that no adverse cardiovascular events were found with this trial could be because the study participants were only taking it for 9 months, the researchers point out. Another trial showed that adverse events occurring only after 1 year of rofecoxib, a cyclooxygenase-2 inhibitor.

In an accompanying editorial, Frank L. Meyskens Jr. M.D., and Christine E. McLaren, M.D., of the University of California, Irvine write that the fact that celecoxib was effective in reducing the number of nonmelanoma skin cancers but not the number of precancerous lesions may suggest that pathways of carcinogenesis differ between early- and late-stage tumor development.

The editorialists say future trials of celecoxib might try lowering the frequency of celecoxib administration, given the adverse cardiovascular events shown by other trials, or use a lower dosage in combination with other compounds with proven efficacy in colorectal adenoma.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Craig A. Elmets, Jaye L. Viner, Alice P. Pentland, Wendy Cantrell, Hui-Yi Lin, Howard Bailey, Sewon Kang, Kenneth G. Linden, Michael Heffernan, Madeleine Duvic, Ellen Richmond, Boni E. Elewski, Asad Umar, Walter Bell, and Gary B. Gordon. Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial. J Natl Cancer Inst, November 29, 2010 DOI: 10.1093/jnci/djq442

Cite This Page:

Journal of the National Cancer Institute. "Celecoxib (Celebrex) may be effective in preventing non-melanoma skin cancers." ScienceDaily. ScienceDaily, 30 November 2010. <www.sciencedaily.com/releases/2010/11/101129160948.htm>.
Journal of the National Cancer Institute. (2010, November 30). Celecoxib (Celebrex) may be effective in preventing non-melanoma skin cancers. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2010/11/101129160948.htm
Journal of the National Cancer Institute. "Celecoxib (Celebrex) may be effective in preventing non-melanoma skin cancers." ScienceDaily. www.sciencedaily.com/releases/2010/11/101129160948.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins